<DOC>
	<DOCNO>NCT01602120</DOCNO>
	<brief_summary>This extension study CFD4870g ( GX01456 ) ass long-term safety tolerability repeat intravitreal administration FCFD4514S patient geographic atrophy . Patients eligible participate complete 18 month treatment assignment study CFD4870g ( GX01456 ) , meet GX28198 eligibility criterion . The anticipated time study treatment 18 month .</brief_summary>
	<brief_title>An Extension Study Evaluate Long-Term Safety FCFD4514S Patients With Geographic Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Previous enrollment completion study CFD4870g ( GX01456 ) without early treatment discontinuation Sufficiently clear ocular medium , adequate pupillary dilation , fixation Early treatment and/or study discontinuation prior completion study CFD4870g ( GX01456 ) Vitrectomy surgery , submacular surgery , surgical intervention AMD study eye Subfoveal focal laser photocoagulation study eye Treatment Visodyne , externalbeam radiation therapy , transpupillary thermotherapy study eye Intravitreal drug delivery FCFD4514S study eye Active wet AMD either eye require antiVEGF treatment</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>